Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Monogram Orthopaedics Inc ( (MGRM) ) is now available.
Monogram Orthopaedics Inc. is set to merge with Zimmer Biomet Holdings, Inc., with the merger agreement initially dated July 11, 2025. On September 4, 2025, Zimmer Biomet withdrew and resubmitted its pre-merger notification to allow the Federal Trade Commission more time for review, a standard procedure in antitrust evaluations. The merger is expected to be completed in the second half of 2025, pending regulatory approvals and shareholder agreement.
The most recent analyst rating on (MGRM) stock is a Buy with a $10.80 price target. To see the full list of analyst forecasts on Monogram Orthopaedics Inc stock, see the MGRM Stock Forecast page.
Spark’s Take on MGRM Stock
According to Spark, TipRanks’ AI Analyst, MGRM is a Neutral.
Monogram Orthopaedics Inc. shows promise due to significant technological advancements and recent regulatory clearances, which are key drivers for potential growth. However, financial instability, regulatory uncertainties, and ongoing profitability challenges weigh heavily on the overall score. The stock’s upward momentum is a positive indicator, but valuation metrics remain weak due to negative earnings and lack of dividends.
To see Spark’s full report on MGRM stock, click here.
More about Monogram Orthopaedics Inc
Monogram Orthopaedics Inc. operates in the medical technology industry, focusing on developing and providing innovative orthopaedic solutions. The company is involved in creating advanced surgical tools and implants, catering to the growing demand for precision and efficiency in orthopaedic procedures.
Average Trading Volume: 374,746
Technical Sentiment Signal: Buy
Learn more about MGRM stock on TipRanks’ Stock Analysis page.